Long-Term Clinical Effectiveness of Ustekinumab in Patients With Crohn’s Disease: A Retrospective Cohort Study

BACKGROUND: This study clarifies the long-term effectiveness of ustekinumab based on real-life data from Japanese Crohn’s disease (CD) patients. METHODS: A total of 137 patients were included, and 124 patients (90.5%) were exposed to anti-tumor necrosis factor-α agents. RESULTS: The clinical remissi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Takahiro, Maemoto, Atsuo, Katsurada, Takehiko, Tanaka, Hiroki, Motoya, Satoshi, Ueno, Nobuhiro, Fujiya, Mikihiro, Ashida, Toshifumi, Hirayama, Daisuke, Nakase, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Observations and Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802107/
https://www.ncbi.nlm.nih.gov/pubmed/36777754
http://dx.doi.org/10.1093/crocol/otaa061
Descripción
Sumario:BACKGROUND: This study clarifies the long-term effectiveness of ustekinumab based on real-life data from Japanese Crohn’s disease (CD) patients. METHODS: A total of 137 patients were included, and 124 patients (90.5%) were exposed to anti-tumor necrosis factor-α agents. RESULTS: The clinical remission rate at week 52 was 32.4% in moderate to severely active CD patients. The achievement of clinical remission for 8 weeks after ustekinumab therapy induction was associated with clinical remission at week 52. Ustekinumab persistence rate at week 104 was 81.4%. CONCLUSION: Ustekinumab is effective and persistent in CD patients with the previous treatment history of several biologics.

Ejemplares similares